Cell line · CVCL_1847
Papers60
1 to 20 of 60
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Selective AUTAC-mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma. | Clin Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KDM6A loss enhances oxidative phosphorylation uncovering tissue-level convergent evolution. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer. | Cancer Metab | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Metal-Free Carbon Monoxide Prodrug Suppresses Metastasis of Pancreatic and Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel defined manganese metabolism-related gene signature for predicting the prognosis of pancreatic ductal adenocarcinoma. | Oncol Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. | JCI Insight | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. | Science | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis. | J Exp Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. | Gut | 2024 | Its Methods give the RRID and name the line | PubMed | |
| BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1847/papers